Biotech Values

[genisi]

Given the increasing number of molecular diagnostic and cytogenetic studies and the availability of superior (to standard chemotherapy) and targeted drugs, pathologists will need to use the minimum amount of tissue required for diagnosis while preserving as much tumor tissue as possible for molecular tests to guide therapy. I assume the most common mutations in EGFR and KRAS genes will be screened first and if negative, and the remaining material is suf?cient, then EML4-ALK translocation will be screened for.